Lupin Limited — Updates, 07-05-2025: Press Release

Lupin has announced a board meeting on the financial results for the quarter and half-year. The company launched Eslicarbazepine Acetate Tablets (200-800 mg) in the U.S. after FDA approval, securing 180 days of shared generic exclusivity. Bioequivalent to Aptiom®, the drug targets partial-onset seizures and has estimated annual U.S. sales of USD 395 million, positioning Lupin well for growth in the neurology segment.